Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA, tariffs
2026 · 2nd Quarter (Apr 1 - June 30)
BAVARIAN NORDIC INC.
Filed by BAVARIAN NORDIC INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Termination
- Posted
- Jul 13, 2026
- Income
- Not reported
- Expenses
- $160,000.00
- Registrant
- BAVARIAN NORDIC INC.
- Client
- BAVARIAN NORDIC INC.
- Filing UUID
- c863b9d5-0fce-4b2b-a551-19c2569ba428
- Termination date
- Jun 30, 2026
Expense method: A
Literal source text
Lobbying issues and bill citations
Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA, tariffs
Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA; tariffs
Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA, tariffs
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.